Effects of 12 months of treatment with disease-modifying anti-rheumatic drugs on low and high density lipoprotein subclass distribution in patients with early rheumatoid arthritis: a pilot study

Abstract

Patients with ERA have increased sdLDL-C levels and decreased HDL-C levels because of decreased concentration of the small HDL-3 subclass. The administration of DMARDs induced a significant increase in HDL-C levels, which was attributed to the increase in large HDL-2 serum concentration.

Positron emission tomography/computed tomography imaging and rheumatoid arthritis

“…After administration of methotrexate and prednisone, patients showed a significant increase in HDL‐C levels . Treatment led to a significant decrease in the inflammatory markers CRP and ESR, as well as in the reduction of DAS‐28 . Similarly, PET/CT images showed intense articular uptake in hands and wrists before anti‐TNF therapy (infliximab).…”

“…The patients also had higher serum levels of total cholesterol, plasma levels of small dense low‐density lipoprotein cholesterol (sdLDL‐C) whereas their serum high‐density lipoprotein cholesterol (HDL‐C) levels were significantly lower compared with controls. After administration of methotrexate and prednisone, patients showed a significant increase in HDL‐C levels . Treatment led to a significant decrease in the inflammatory markers CRP and ESR, as well as in the reduction of DAS‐28 .…”

According to the Materials of the 2015/2016 New European League Against Rheumatism (Eular) Guidelines for Reducing Cardiovascular Risk in Patients With Inflammatory Arthritis: General Characterization and Discussion Problems

“…Пациенты с РА и высокой активно-стью заболевания обычно имеют более низкие уровни ОХС и ХС ЛПНП в крови по сравнению с общей популя-цией, в то время как риск ССЗ повышен [53,55,56]. При РА также наблюдаются снижение концентрации ХС ЛПВП и повышение уровня триглицеридов по сравнению с их уровнем у здоровых лиц [57,58]. Подавление активно-сти болезни оказывает влияние на липидный профиль кро-ви.…”

“…Подавление активно-сти болезни оказывает влияние на липидный профиль кро-ви. Применение ингибиторов ФНОα и БПВП (в основном MT) ассоциируется с увеличением концентрации ОХС, ХС ЛПНП и, в большей степени, ХС ЛПВП, что улучшает от-ношение ОХС/ХС ЛПВП [57][58][59][60][61][62][63][64][65]. В исследованиях сооб-щалось о положительном эффекте РТМ, тоцилизумаба и тофацитиниба на показатели липидного спектра крови [47,[66][67][68][69][70][71][72].…”

Effectiveness of methotrexate therapy with occasional corticosteroid in rheumatoid arthritis

“…,54,55 Filippatos et al3 reported improvement in HDL-c levels after disease modifying antirheumatic drug therapy; however the mechanisms that lead to decreased HDL-c are not well established. Regardless of the…”